{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:23:11Z","timestamp":1783714991507,"version":"3.55.0"},"reference-count":62,"publisher":"Nihon University School of Dentistry","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Oral Science","J Oral Sci"],"published-print":{"date-parts":[[2015]]},"DOI":"10.2334\/josnusd.57.161","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T22:02:20Z","timestamp":1442268140000},"page":"161-168","source":"Crossref","is-referenced-by-count":12,"title":["An update on myasthenia gravis, challenging disease for the dental profession"],"prefix":"10.2334","volume":"57","author":[{"given":"Alessandro","family":"Tamburrini","sequence":"first","affiliation":[{"name":"Thoracic Surgery Division, Multidisciplinary Myasthenia Gravis Unit, Tor Vergata University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Tacconi","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Division, Multidisciplinary Myasthenia Gravis Unit, Tor Vergata University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Barlattani","sequence":"additional","affiliation":[{"name":"Special Diseases in Odontostomatology, Tor Vergata University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"C. Mineo","sequence":"additional","affiliation":[{"name":"Thoracic Surgery Division, Multidisciplinary Myasthenia Gravis Unit, Tor Vergata University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1160","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Patton LL, Howard JF Jr (1997) Myasthenia gravis: dental treatment considerations. Spec Care Dentist 17, 25-32.","DOI":"10.1111\/j.1754-4505.1997.tb00532.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Carr AS, Cardwell CR, McCarron PO, McConville J (2010) A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 10, 46.","DOI":"10.1186\/1471-2377-10-46"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48-49, 143-148.","DOI":"10.1016\/j.jaut.2014.01.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Drachman DB (1994) Myasthenia gravis. N Engl J Med 330, 1797-1810.","DOI":"10.1056\/NEJM199406233302507"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Verschuuren JJGM, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P et al. (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimm Rev 12, 918-923.","DOI":"10.1016\/j.autrev.2013.03.001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7, 365-368.","DOI":"10.1038\/85520"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP et al. (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131, 1940-1952.","DOI":"10.1093\/brain\/awn092"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69, 418-422.","DOI":"10.1002\/ana.22312"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Le Panse R, Bismuth J, Cizeron-Clairac G, Weiss JM, Cufi P, Dartevelle P et al. (2010) Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 43, 401-412.","DOI":"10.3109\/08916930903563491"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Str\u00f6bel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmum Rev 12, 875-884.","DOI":"10.1016\/j.autrev.2013.03.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Berrith-Aknin S, Ragheb S, Le Panse R, Lisak RP (2013) Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 12, 885-893.","DOI":"10.1016\/j.autrev.2013.03.011"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Luchanok U, Kaminski HJ (2008) Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 21, 8-15.","DOI":"10.1097\/WCO.0b013e3282f4098e"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Schneider PE (1983) Dental management of a child with severe myasthenia gravis. Spec Care Dentist 3, 266-270.","DOI":"10.1111\/j.1754-4505.1983.tb00115.x"},{"key":"14","unstructured":"14. Calcaterra TC, Stern F, Herrman C Jr, Mulder DG (1972) The otolaryngologist\u2019s role in myasthenia gravis. Trans Am Acad Ophthalmol Otolaryngol 76, 308-312."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I et al. (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48, 1253-1260.","DOI":"10.1212\/WNL.48.5.1253"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D (1997) Therapy of myasthenic crisis. Crit Care Med 25, 1228-1235.","DOI":"10.1097\/00003246-199707000-00027"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminsky HJ, Keesey JC, Penn AS et al. (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55, 16-23.","DOI":"10.1212\/WNL.55.1.16"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Alkhawajah NM, Oger J (2013) Late-onset myasthenia gravis: a review when incidence in the older adults keeps increasing. Muscle Nerve 48, 705-710.","DOI":"10.1002\/mus.23964"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Statland JM, Ciafaloni E (2013) Myasthenia gravis: five new things. Neurol Clin Pract 3, 126-133","DOI":"10.1212\/CPJ.0b013e31828d9fec"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaloglu P, Ozdemir C et al. (2007) Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68, 609-611.","DOI":"10.1212\/01.wnl.0000254620.45529.97"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hopkins LC (1994) Clinical features of myasthenia gravis. Neurol Clin 12, 243-261.","DOI":"10.1016\/S0733-8619(18)30095-1"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Vincent A, Bowen J, Newsom-Davis J, McCoville J (2003) Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2, 99-106.","DOI":"10.1016\/S1474-4422(03)00306-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D (1992) Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 15, 720-724.","DOI":"10.1002\/mus.880150616"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Howard JF Jr (2013) Electrodiagnosis of disorders of neuromuscular transmission. Phys Med Rehabil Clin N Am 24, 169-192.","DOI":"10.1016\/j.pmr.2012.08.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Oh SJ, Hatanaka Y, Hemmi S, Young AM, Scheufele ML, Nations SP et al. (2006) Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis. Muscle Nerve 33, 500-504.","DOI":"10.1002\/mus.20498"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Juel VC, Massey JM (2007) Myasthenia gravis. Orphanet J Rare Dis 2, 44.","DOI":"10.1186\/1750-1172-2-44"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kissel JT, Franklin GM (2000) Treatment of myasthenia gravis: a call to arms. Neurology 55, 3-4.","DOI":"10.1212\/WNL.55.1.3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Vincent A, Palace J, Hilton-Jones D (2001) Myasthenia gravis. Lancet 357, 2122-2128.","DOI":"10.1016\/S0140-6736(00)05186-2"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sieb JP (2005) Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 5, 303-307.","DOI":"10.1016\/j.coph.2005.01.010"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Lewis RA (2013) Myasthenia gravis: new therapeutic approaches based on pathophysiology. J Neurol Sci 333, 93-98.","DOI":"10.1016\/j.jns.2013.06.018"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Blalock A, Mason MF, Morgan HJ, Riven SS (1939) Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg 110, 544-561.","DOI":"10.1097\/00000658-193910000-00005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ambrogi V, Mineo TC (2012) Active ectopic thymus predicts poor outcome after thymectomy in class III myasthenia gravis. J Thorac Cardiovasc Surg 143, 601-606.","DOI":"10.1016\/j.jtcvs.2011.04.050"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Mineo TC, Ambrogi V (2013) Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg 145, 1319-1324.","DOI":"10.1016\/j.jtcvs.2012.12.053"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Jamal BT, Herb K (2009) Perioperative management of patients with myasthenia gravis: prevention, recognition, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107, 612-615.","DOI":"10.1016\/j.tripleo.2009.01.015"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M et al. (1996) Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg 62, 853-859.","DOI":"10.1016\/S0003-4975(96)00376-1"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Weijnen FG, van der Bilt A, Kuks JB, van der Glas HW, Oudenaarde I, Bosman F (2002) Masticatory performance in patients with myasthenia gravis. Arch Oral Biol 47, 393-398.","DOI":"10.1016\/S0003-9969(02)00014-6"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Yarom N, Barnea E, Nissan J, Gorsky M (2005) Dental management of patients with myasthenia gravis: a literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100, 158-163.","DOI":"10.1016\/j.tripleo.2005.01.003"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Patil PM, Singh G, Patil SP (2012) Dentistry and the myasthenia gravis patient: a review of the current state of the art. Oral Surg Oral Med Oral Pathol Oral Radiol 114, e1-8.","DOI":"10.1016\/j.tripleo.2011.08.023"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sasakura Y, Kumasaka S, Takashashi T, Shindo J (2000) Myasthenia gravis associated with reduced masticatory function. Int J Oral Maxillofac Surg 29, 381-383","DOI":"10.1016\/S0901-5027(00)80058-2"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Khan KA, Bennett JD (2014) Undiagnosed myasthenia gravis owing to a very unusual primary presentation. Oral Surg Oral Med Oral Pathol Oral Radiol 118, e101-104.","DOI":"10.1016\/j.oooo.2014.02.027"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. van der Pols-Vijlbrief R, Wijnhoven HA, Schaap LA, Terwee CB, Visser M (2014) Determinants of protein-energy malnutrition in community-dwelling older adults: a systematic review of observational studies. Ageing Res Rev 18, 112-131.","DOI":"10.1016\/j.arr.2014.09.001"},{"key":"42","unstructured":"42. Wang J, Luo B, Xie Y, Hu HY, Feng L, Li ZN (2014) Evaluation methods on the nutritional status of stroke patients. Eur Rev Med Pharmacol Sci 18, 3902-3907."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Lindroos E, Saarela RK, Soini H, Muurinen S, Suominen MH, Pitk\u00e4l\u00e4 KH (2014) Caregiver-reported swallowing difficulties, malnutrition, and mortality among older people in assisted living facilities. J Nutr Health Aging 18, 718-722.","DOI":"10.1007\/s12603-014-0506-4"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Saarela RK, Soini H, Hiltunen K, Muurinen S, Suominen M, Pitk\u00e4l\u00e4 K (2014) Dentition status, malnutrition and mortality among older service housing residents. J Nutr Health Aging 18, 34-38.","DOI":"10.1007\/s12603-013-0358-3"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Pr\u00eacheur I, Chevalier M (2015) The fight against malnutrition in older adults: new approaches in dentistry. Geriatr Psychol Neuropsychiatr Vieil 13, 22-30.","DOI":"10.1684\/pnv.2015.0515"},{"key":"46","unstructured":"46. Rai B (2006) Myasthenia gravis: challenge to dental profession. Internet J Acad Phys Assist 6, 18-20."},{"key":"47","unstructured":"47. Mincewicz G, Aloszko A, Nyka W, Bilinska M, Krzykowski G, Nyka WM (2007) The comparison of selected spirometric parameters with functional muscles exercise evaluation in patients mith myasthenia. Pol Merkur Lekarski 22, 177-181."},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Burns TM, Grouse CK, Wolfe GI, Conaway MR, Sanders DB; MG Composite and MG-OL15 Study Group (2011) The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43, 14-18.","DOI":"10.1002\/mus.21883"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Burns TM (2012) The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann NY Acad Sci 1274, 99-106.","DOI":"10.1111\/j.1749-6632.2012.06812.x"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Muppidi S (2012) The myasthenia gravis--specific activities of daily living profile. Ann N Y Acad Sci 1274, 114-119.","DOI":"10.1111\/j.1749-6632.2012.06817.x"},{"key":"51","unstructured":"51. Abel M, Eisenkraft JB (2002) Anesthetic implications of myasthenia gravis. Mt Sinai J Med 69, 31-37."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Dillon FX (2004) Anesthesia issues in the perioperative management of myasthenia gravis. Semin Neurol 24, 83-94.","DOI":"10.1055\/s-2004-829587"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Harnett MT, Chen W, Smith SM (2009) Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness. Neuropharmacology 57, 502-505.","DOI":"10.1016\/j.neuropharm.2009.07.031"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Sieb JP (1998) Fluoroquinolone antibiotics block neuromuscular transmission. Neurology 50, 804-807.","DOI":"10.1212\/WNL.50.3.804"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Jones SC, Sorbello A, Boucher RM (2011) Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 34, 839-847.","DOI":"10.2165\/11593110-000000000-00000"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Perrot X, Bernard N, Vial C, Antoine JC, Laurent H, Vial T et al. (2006) Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 67, 2256-2258.","DOI":"10.1212\/01.wnl.0000247741.72466.8c"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Jennett AM, Bali D, Jasti P, Shah B, Browning LA (2006) Telithromycin and myasthenic crisis. Clin Infect Dis 43, 1621-1622.","DOI":"10.1086\/509646"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Argov Z, Brenner T, Abramsky O (1986) Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol 43, 255-256.","DOI":"10.1001\/archneur.1986.00520030045010"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60. Mehndiratta MM, Pandey S, Kuntzer T (2014) Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev, doi: 10.1002\/14651858.CD006986.pub3.","DOI":"10.1002\/14651858.CD006986.pub3"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61. Jani-Acsadi A, Lisak RP (2010) Myasthenia gravis. Curr Treat Options Neurol 12, 231-243.","DOI":"10.1007\/s11940-010-0070-0"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62. Weksler B, Lu B (2014) Alterations of the immune system in thymic malignancies. J Thorac Oncol 9, S137-142.","DOI":"10.1097\/JTO.0000000000000299"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63. Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52, 90-100.","DOI":"10.1016\/j.jaut.2013.12.011"}],"container-title":["Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/57\/3\/57_161\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T14:32:29Z","timestamp":1567175549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/josnusd\/57\/3\/57_161\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2334\/josnusd.57.161","relation":{},"ISSN":["1343-4934","1880-4926"],"issn-type":[{"value":"1343-4934","type":"print"},{"value":"1880-4926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}